Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs
Key Highlights
- ➤Nine-month revenue $0.8 million, down $2.4 million year over year
- ➤Nine-month net loss $10.5 million versus $2.5 million in 2025
- ➤Cash, equivalents and short-term deposits totaled approximately $9.2 million
- ➤aGVHD program produced nanomolar-potency candidates with encouraging preliminary ADME and toxicology profiles
- ➤AgPlenus compounds reduced Septoria disease severity by up to 75% versus untreated controls
Expert Statements
Ofer Haviv, President and CEO of Evogene
“During the third quarter, we continued to advance our strategy of leveraging our proprietary AI-driven discovery platform, ChemPass AI™, to develop innovative small-molecule-based products with significant commercial potential.”
Ofer Haviv, President and CEO of Evogene
“Alongside our collaborative discovery activities, we are advancing two internal development programs that represent an important component of our strategy to build a pipeline of proprietary assets fully owned and managed by Evogene.”
Ofer Haviv, President and CEO of Evogene
“The first one is our internal drug discovery program targeting acute graft-versus-host disease (aGVHD), a serious medical condition associated with significant unmet medical need.”
Ofer Haviv, President and CEO of Evogene
“Within just several months, Using ChemPass AI™, we generated a series of novel, small-molecule candidates, that demonstrated biological potency, at nanomolar concentrations, as well as encouraging preliminary ADME and toxicology profiles.”
Ofer Haviv, President and CEO of Evogene
“We are now focused on further optimizing these molecules, identifying the most promising candidates, and advancing the program toward IND-enabling studies.”
Ofer Haviv, President and CEO of Evogene
“The second program, conducted through our subsidiary AgPlenus, focuses on discovering fungicides with new modes of action targeting Septoria tritici blotch, a major wheat disease for which resistance to existing fungicides is a growing challenge.”
Ofer Haviv, President and CEO of Evogene
“Using ChemPass AI for Ag™, AgPlenus identified compounds that showed promising activity against fungicide-resistant Septoria strains.”
Ofer Haviv, President and CEO of Evogene
“Selected compounds also reduced disease severity by up to 75%, compared to untreated controls, in plant tissue assays and demonstrating activity against additional fungal pathogens, indicating broader fungicidal potential.”
Ofer Haviv, President and CEO of Evogene
“The progresses achieved across these initiatives demonstrates the ability of ChemPass AI™ and ChemPass AI for Ag™ to translate computational discovery into experimentally validated molecules exhibiting promising biological activity.”
Ofer Haviv, President and CEO of Evogene
“More importantly, these programs reflect our strategic focus on converting technological capabilities into differentiated, proprietary product candidates offering meaningful commercial potential, ultimately creating long-term value for Evogene and its shareholders.”
Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs PR Newswire
Company advances its internally developed drug discovery program targeting acute graft-versus-host disease (aGVHD) and AgPlenus' fungicide discovery programs targeting novel MoA against Septoria
Get started
Create a free account to read the full story.
